cagrilintide

Compound Overview

Cagrilintide is an acylated, long-acting analog of human amylin. In laboratory research models, it binds amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors, where it modulates appetite, gastric emptying, and postprandial glucose signaling. Its fatty acid acylation supports an extended research half-life through albumin binding.

Research Background & Published Literature

Cagrilintide has been evaluated within the CagriSema combination research approach alongside semaglutide. Phase 2 and 3 clinical data have examined amylin-based signaling as a pathway that can be studied in parallel with incretin-based approaches.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Enebo et al. (2021) — Lancet
• Lau et al. (2021) — Lancet

Storage, Handling & Stability Guidelines

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

• Keep ambient-temperature handling time as short as practical to support compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Quality Assurance & Lab Verification

A finalized public Certificate of Analysis is available for this catalog item. Review the public COA for the applicable lot. Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier.